BOSTON - The Massachusetts federal judge overseeing federal drug pricing litigation on May 31 denied a motion by two whistle-blowers to reopen a settled case involving hemophilia drugs made by Baxter Healthcare Corp., finding that a specialty pharmacy was the first to file allegations involving the drugs (In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL Docket No. 1456, No. 01-12257, Subcategories No. 08-11200 and No. 10-11186, United States of America ex rel. Linette Sun, et al. v. Baxter Healthcare Corporation, United States of America ex rel. Ven-A-Care of the Florida Keys, Inc. v. Baxter Healthcare Corporation, D. Mass.; 2013 U.S. Dist. LEXIS 76750).